Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

The Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) study was designed to better understand the types of patients who are begun on omalizumab in the real-world setting, including asthma burden, comorbidities, and biomarker profiles, and to evaluate what clinical parameters might be associated with better outcomes with the use of this biologic agent. In this month's issue of the Annals, Griffin et al1 report on the first of these 2 outcomes.

http://ift.tt/2krEw2R